NCT06680206 is a clinical trial of Rimegepant in Migraine, sponsored by Pfizer.

Who is sponsoring NCT06680206?

NCT06680206 is sponsored by Pfizer.

What drugs are being tested in NCT06680206?

Interventions in NCT06680206: Rimegepant, Triptans.

Is NCT06680206 still recruiting?

NCT06680206 is currently completed. Last updated 22 January 2026.

Are results published for NCT06680206?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-01-22 · How we verify

NCT06680206

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

Completed Results posted Last updated 22 January 2026

What this trial tests

trial testing Rimegepant in Migraine in 1,395 participants. Completed in 20 November 2024.

Timeline

10 October 2024

Primary endpoint
20 November 2024

20 November 2024

Quick facts

Lead sponsor	Pfizer
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,395
Start date	10 October 2024
Primary completion	20 November 2024
Estimated completion	20 November 2024
Sites	1 location across United States

Drugs / interventions tested

Rimegepant (rimegepant) — full drug profile →
Triptans (triptans) — full drug profile →

Conditions studied

Migraine — all drugs for Migraine →

Sponsor

Pfizer — full company profile →

Who can join

18 and older, any sex, with Migraine. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants According to Migraine Medication Type (Prescription Drug or Over the Counter [OTC]) Primary · At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Number of participants according to migraine medication type: 1) as prescription drug only, 2) as OTC only or 3) as both prescription drug and OTC based on the use of migraine medication classes is reported in this outcome measure. Analysis was performed using inverse probability treatment weighting (IPTW) method to adjust for confounding by the covariates.

Group	Value	95% CI
Rimegepant	74
Triptans	682
Rimegepant	61
Triptans	578
Rimegepant	0
Triptans	0

Number of Participants According to Migraine Treatment Type (Acute or Prevention) Primary · At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Number of participants according to migraine treatment type: 1) acute use only, 2) prevention use only, or 3) both acute and prevention use based on the use of migraine medication classes is reported in this outcome measure. Acute treatments included: triptans, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, barbiturates, ergots, gepants \[acute; including Nurtec\], ditan, combination analgesics, and other acute treatment; preventive treatment included: anticonvulsants, beta blocker, antidepressant, calcitonin gene-related peptide antibodies monoclonal antibodies (CGRP mAb), botox, an

Group	Value	95% CI
Rimegepant	0
Triptans	837
Rimegepant	0
Triptans	0
Rimegepant	135
Triptans	423

Total Number of Acute Migraine Agent Drug Classes Used Primary · At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Total number of distinct acute migraine agent drug classes used by participants is reported as mean in this outcome measure. Acute migraine agents included: triptans, NSAIDs, opioids, barbiturates, ergots, gepants \[acute; including Nurtec\], ditan, combination analgesics, and other acute treatment. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Group	Value	95% CI
Rimegepant	2.1	± 1.2
Triptans	2.2	± 1.2

Number of Participants According to Number of Acute Migraine Agent Drug Classes Used Primary · At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Number of participants categorized by the number of distinct acute migraine agent drug classes used is reported in this outcome measure. Categories included 1 drug class, 2 or more drug classes, and 3 or more drug classes. Analysis was performed using IPTW method to adjust for confounding by the covariates.

1 drug class

Group	Value	95% CI
Rimegepant	51
Triptans	431

2 or more drug classes

Group	Value	95% CI
Rimegepant	84
Triptans	829

3 or more drug classes

Group	Value	95% CI
Rimegepant	40
Triptans	406

Total Number of Prevention Migraine Agent Drug Classes Used Primary · At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Preventive migraine agents included: anticonvulsants, beta blocker, antidepressant, CGRP mAb, botox, and gepant \[prevention treatment including Nurtec\]. Total number of distinct preventive migraine agent drug classes used by participants is reported as mean in this outcome measure. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Group	Value	95% CI
Rimegepant	1.5	± 0.7
Triptans	0.5	± 0.8

Number of Participants According to Number of Prevention Migraine Agent Drug Classes Used Primary · At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Number of participants categorized by the number of distinct prescription preventive migraine agent drug classes used reported in this outcome measure. Categories included use of 1 drug class, 2 or more drug classes, and 3 or more drug classes. Analysis was performed using IPTW method to adjust for confounding by the covariates.

1 drug class

Group	Value	95% CI
Rimegepant	79
Triptans	297

2 or more drug classes

Group	Value	95% CI
Rimegepant	56
Triptans	126

3 or more drug classes

Group	Value	95% CI
Rimegepant	12
Triptans	25

Number of Participants According to Current Migraine Treatments Primary · At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Number of participants according to current migraine treatments on drug classes including: Nurtec (rimegepant) only, acute agents, triptans, NSAIDs, opioids, barbiturates, ergots, gepants \[acute; including Nurtec\], ditan, combination analgesics, and other acute treatment (aspirin lysine/metoclopramide hydrochloride monohydrate or indometacin/caffeine/prochlorperazine), prevention agents (anticonvulsants, beta-blocker, antidepressant, CGRP mAb, botox, and gepant) are reported in this outcome measure. One participant could receive more than one migraine treatment. Analysis was performed using

Nurtec (rimegepant) only

Group	Value	95% CI
Rimegepant	135
Triptans	0

Acute agents

Group	Value	95% CI
Rimegepant	135
Triptans	1259

Triptans

Group	Value	95% CI
Rimegepant	0
Triptans	1260

NSAIDs

Group	Value	95% CI
Rimegepant	22
Triptans	187

Opioids

Group	Value	95% CI
Rimegepant	10
Triptans	132

Barbiturates

Group	Value	95% CI
Rimegepant	6
Triptans	96

Ergots

Group	Value	95% CI
Rimegepant	4
Triptans	35

Gepants (acute; including Nurtec)

Group	Value	95% CI
Rimegepant	135
Triptans	33

Number of Participants According to Treatment Satisfaction of Migraine Drug Class Primary · At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Number of participants according to treatment satisfaction for the migraine drug classes including: acute agents, NSAIDs, opioids, barbiturates, ergots, gepants (acute), ditans, combination analgesics, other, prevention agents, anticonvulsants, beta blockers, antidepressants, CGRPs mAb, botox, and gepant reported in this outcome measure. Treatment satisfaction for each of the migraine drug class was categorized as: extremely dissatisfied, very dissatisfied, somewhat dissatisfied, neither dissatisfied nor satisfied, somewhat satisfied, very satisfied, extremely satisfied. Analysis was performed

Current migraine satisfactions - Acute agents

Group	Value	95% CI
Rimegepant	3
Triptans	97
Rimegepant	3
Triptans	45
Rimegepant	6
Triptans	92
Rimegepant	14
Triptans	145

Current migraine satisfactions - NSAIDs

Group	Value	95% CI
Rimegepant	0
Triptans	15
Rimegepant	1
Triptans	13
Rimegepant	2
Triptans	8
Rimegepant	4
Triptans	24

Current migraine satisfactions - Opioids

Group	Value	95% CI
Rimegepant	0
Triptans	22
Rimegepant	0
Triptans	13
Rimegepant	2
Triptans	5
Rimegepant	3
Triptans	45

Current migraine satisfactions - Barbiturates

Group	Value	95% CI
Rimegepant	0
Triptans	6
Rimegepant	1
Triptans	40
Rimegepant	0
Triptans	11
Rimegepant	2
Triptans	10

Current migraine satisfactions - Ergots

Group	Value	95% CI
Rimegepant	1
Triptans	0
Rimegepant	0
Triptans	2
Rimegepant	1
Triptans	0
Rimegepant	0
Triptans	0

Current migraine satisfactions - Gepants (acute; including Nurtec)

Group	Value	95% CI
Rimegepant	2
Triptans	6
Rimegepant	1
Triptans	0
Rimegepant	4
Triptans	0
Rimegepant	6
Triptans	3

Current migraine satisfactions - Ditans

Group	Value	95% CI
Rimegepant	0
Triptans	0
Rimegepant	0
Triptans	0
Rimegepant	0
Triptans	0
Rimegepant	0
Triptans	0

Current migraine satisfactions - Combination Analgesics

Group	Value	95% CI
Rimegepant	0
Triptans	11
Rimegepant	1
Triptans	13
Rimegepant	2
Triptans	21
Rimegepant	4
Triptans	40

Number of Participants According to Current Migraine Treatments on OTC Class Primary · At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

Participants were categorized based on current use of OTC migraine treatments, including analgesics (acetaminophen only), analgesics (combination), NSAIDs, and other OTCs.

Analgesics (acetaminophen only)

Group	Value	95% CI
Rimegepant	34
Triptans	198

Analgesics (Combination)

Group	Value	95% CI
Rimegepant	28
Triptans	221

NSAIDs

Group	Value	95% CI
Rimegepant	32
Triptans	320

Other

Group	Value	95% CI
Rimegepant	0
Triptans	4

Number of Participants According to Treatment Satisfaction of Analgesics (Acetaminophen Only) Primary · At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study

Number of participants according to treatment satisfaction for analgesics (acetaminophen only) is reported in this outcome measure. Treatment satisfaction was categorized as: extremely dissatisfied, very dissatisfied, somewhat dissatisfied, neither dissatisfied nor satisfied, somewhat satisfied, very satisfied, extremely satisfied. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Group	Value	95% CI
Rimegepant	3
Triptans	13
Rimegepant	2
Triptans	3
Rimegepant	6
Triptans	13
Rimegepant	10
Triptans	44

Number of Participants According to Treatment Satisfaction to Rimegepant or Triptans Primary · At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study

Number of participants according to treatment satisfaction for rimegepant or triptans is reported in this outcome measure. Treatment satisfaction was categorized as: extremely dissatisfied, very dissatisfied, somewhat dissatisfied, neither dissatisfied nor satisfied, somewhat satisfied, very satisfied, extremely satisfied. Analysis was performed using IPTW method to adjust for confounding by the covariates.

Group	Value	95% CI
Rimegepant	1
Triptans	74
Rimegepant	1
Triptans	46
Rimegepant	4
Triptans	69
Rimegepant	7
Triptans	101

Research and Development (RAND-36) Physical Component Score, Mental Component Score and Global Health Score - Primary Analysis Primary · At the time of survey during 1 year of data identification (Year 2023); available retrospective data was evaluated over approximately 1.41 months of this observational study.

RAND-36=standardized survey evaluating 8 domains of functional health and well-being: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. Score for each of the 8 domains were scaled from 0=worst condition to 100=best condition, higher scores indicated better health status. These 8 domains were summarized as summary scores: physical component scores (derived from physical functioning, role physical, bodily pain, general health), mental component scores (derived from social functioning, role emotional mental health and

Mental summary composite T score

Group	Value	95% CI
Rimegepant	38.2	± 12
Triptans	37.1	± 12.6

Physical summary composite T score

Group	Value	95% CI
Rimegepant	39.5	± 12
Triptans	39.8	± 11.9

Global health composite T score

Group	Value	95% CI
Rimegepant	37.2	± 12.4
Triptans	36.7	± 12.7

Sponsor's own description

This is a cross-sectional study using the cross-sectional 2023 National Health and Wellness Survey (NHWS) data from the US, with a large and nationally representative population (N=75,007). All data from the NHWS are reported by respondents, who are recruited through an existing, general-purpose, web-based, consumer panel via opt-in e-mails, co-registration with panel partners, e-newsletter campaigns, banner placements, and affiliate networks. All respondents explicitly agree to be a panel member, register with the panel through a unique e-mail address, and complete an in-depth demographic registration profile. This analysis will focus on respondents who self-report having migraine diagnosed by a physician. Individuals who use rimegepant for acute treatment of migraine will be compared with those who use triptans for acute treatment of migraine. Outcomes of interest include treatment satisfaction, healthcare resource utilization (HCRU), quality of life (QoL), work productivity loss, and migraine-specific disability outcomes. Inverse probability of treatment weighting (IPTW) will be used to adjust for differences that may exist between rimegepant and triptan users prior to comparing outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Rimegepant

Trials testing the same drug.

NCT06999252 — Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients · Phase 2 · not yet recruiting
NCT06985342 — Acute Migraine Treatment in the ED With Gepants · Phase 4 · recruiting
NCT06992674 — The R-E-V-I-V-A-L Study · Phase 2 · active not recruiting
NCT06748664 — A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experiment · Phase 2 · not yet recruiting
NCT06641466 — A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual · Phase 3 · recruiting

Other recruiting trials for Migraine

Currently open trials in the same condition.

NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
NCT07343427 — Impact of GON PRF on Central Sensitization in Migraine Patients · NA · active not recruiting
NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
NCT07385755 — Desvenlafaxine for Preventive Treatment of Frequent Migraines · NA · active not recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06680206 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 22 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06680206.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing